Search

Background: Spasticity and muscle weakness are the most disabling symptoms in people with Multiple Sclerosis (pwMS), frequently affecting lower limbs and causing motor impairments, fatigue and increased risk of falls. Previous epidemiological studies on pwMS reported prevalence of spasticity and other symptoms but scarce information is available about combined patterns of muscle weakness and spasticity, symmetry and regional localization., Objectives: To describe the prevalent combined patterns of muscle weakness and spasticity in pwMS in order to focus attention on their functional balance before spasticity treatment., Methods: pwMS with lower limb spasticity, 3.5 ≤ Expanded-Disability-Status Scale (EDSS) ≤ 6.5 were recruited. Data regarding muscle weakness and spasticity, symmetry and involvement of other functional systems were collected. Prevalence analysis was performed., Results: Three-hundred pwMS were included. Muscle weakness and spasticity occurred mostly asymmetrically with a prevalence of paraparesis. Incidence of both symptoms increase with higher EDSS, particularly of muscle weakness. Twelve prevalent combined patterns were identified, with highest incidence of combinations characterized by "distal-intermediate spasticity and diffuse weakness" (29.3%), "diffuse spasticity and weakness" (13.7%), "distal spasticity and diffuse weakness" (11.7%)., Conclusions: This study highlighted the most prevalent combined patterns of weakness and spasticity, useful in clinical practice for pwMS' assessment by supporting optimal planning of specific pharmacologic and rehabilitative treatments., Competing Interests: Declarations. Conflicts of interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Ethical approval: This study was conducted in accordance with the Declaration of Helsinki. All patient data come from previous studies on MS spasticity in the three Italian centers already approved from the respective Ethics Committees (University of Campania “L. Vanvitelli”: 100/2018; Sapienza University of Rome: 5769/2020; University of Cagliari, ATS Sardinia: 198/2019/EC). Consent to participate: Informed consent was obtained from all individual participants included in the previous study., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)

Nociplastic pain has been introduced by the IASP as a third category of pain, distinct from nociceptive and neuropathic pain. Pathogenetically, it is considered to be a continuum of these two types of pain after becoming chronic. Repetitive peripheral painful stimulation causes a central sensitization with hypersensitivity of the corresponding spinal metamer or brain region. Therefore, signs of altered nociception, such as allodynia, may be found on the tissues of the related dermatome, myotome and sclerotome, and characterize nociplastic pain. This kind of pain was found in over 20% of people with multiple sclerosis (pwMS), a demyelinating autoimmune disease that affects the central nervous system. Nociplastic pain may be an amplifier of spasticity, the main pyramidal symptom that affects about 80% of pwMS. This article details the case of a 36-year-old woman with multiple sclerosis who was affected by spasticity and non-specific pain of the lower limbs, disabling on walking. Previous analgesic and muscle relaxant treatment had no benefits. The diagnosis of nociplastic pain on the cutaneous tissue of the anterolateral region of the left thigh and its treatment with intradermal normal saline injection on the painful skin area showed immediate and lasting effects on pain and spasticity, improving significantly the patient's balance and walking, as assessed by a 3D motion analysis and rating scales.

Background: Spasticity in people with Multiple Sclerosis (pwMS) is one of the most disabling symptoms on walking ability and balance. Among the systemic antispastic drugs, Nabiximols showed a good tolerability, safety profile and relevant efficacy. A few studies assessed long-term effects of this drug through clinical scales and instrumental tools, but no study investigated short-term effects. The aim of our study is to quantitatively evaluate the immediate effects of Nabiximols on walking and balance and their maintenance after 4 weeks in pwMS and spasticity., Methods: pwMS were enrolled and randomized in 2 treatment groups: Sativex (SG) and control (CG) group. All patients were assessed at T0 (before the first Sativex puff), T1(after 45 minutes) and T2 (after 4 weeks of treatment) using clinical scales and 3d-Gait Analysis . Then, the patients treated with Sativex, were divided into 5 subgroups according to Numeric Rating Scale for spasticity (NRSs) and Berg Balance Score (BBS) response: NRSs responder[1] and non-[2]; BBS responders[3] and non-[4]; NRSs-BBS responders[5]., Results: 32 pwMS (22 SG, 10 CG) were recruited. Significant improvements were found between T0 and T1 in SG compared to CG in a few clinical and kinematic parameters. Larger significant differences were found for NRSs and BBS responders' groups versus CG. Eventually, no significant differences were found comparing the results between T1 and T2, suggesting the persistence of the improvements emerged at T1., Conclusion: These results quantitatively demonstrated a short time effect of Nabiximols on balance and walking of pwMS, which is mantained after 4 weeks. Patients identified as responder by combination of NRSs and BBS showed the best efficacy. These findings may suggest how to early select the real responders in order to improve the adherence and cost-effectiveness of the therapy., (Copyright © 2021. Published by Elsevier B.V.)